论文部分内容阅读
凡符合全国病毒性肝炎防治方案诊断标准的HBsAg携带者,慢性迁延性肝炎、慢性活动性肝炎病例,以RHA法检测HBsAg 1:64以上者均列为观察对象,共80例。随机抽样分成乙肝特异性转移因子组(40例)和肝必复组(40例)经一个月治疗。其结果,乙肝特异性转移因子组HBsAg转阴率和下降率分别为32.5％及45,有效率77.5％,与肝必复组比较差异非常显著(P<0.01),此外, 对血清GPT有一定的下降及恢复作用,尤以HBsAg转阴病例为显著。
All patients with HBsAg carriers, chronic persistent hepatitis, chronic active hepatitis who meet the diagnostic criteria of national viral hepatitis prevention and treatment programs, and the ratio of HBsAg 1:64 detected by RHA method were all included in the observation group, 80 cases in total. Randomly divided into hepatitis B-specific transfer factor group (40 cases) and liver will be the complex group (40 cases) after a month of treatment. As a result, the HBsAg negative rate and the decrease rate of HBsAg-specific transfer factor group were 32.5% and 45, respectively, and the effective rate was 77.5%, which was significantly different from that of the liver-repressing group (P <0.01) Of the decline and recovery, especially in HBsAg negative cases were significant.